We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers.
- Authors
Wilson, Wyndham H; Dunleavy, Kieron; Pittaluga, Stefania; Hegde, Upendra; Grant, Nicole; Steinberg, Seth M; Raffeld, Mark; Gutierrez, Martin; Chabner, Bruce A; Staudt, Louis; Jaffe, Elaine S; Janik, John E
- Abstract
To assess the clinical outcome and the influence of biomarkers associated with apoptosis inhibition (Bcl-2), tumor proliferation (MIB-1), and cellular differentiation on the outcome with dose-adjusted (DA) EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) plus rituximab (R) infusional therapy in diffuse large B-cell lymphoma (DLBCL) with analysis of germinal center B-cell (GCB) and post-GCB subtypes by immunohistochemistry.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Vol 26, Issue 16, p2717
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2007.13.1391